5TRU
Structure of the first-in-class checkpoint inhibitor Ipilimumab bound to human CTLA-4
Summary for 5TRU
Entry DOI | 10.2210/pdb5tru/pdb |
Descriptor | Ipilimumab Fab light chain, Ipilimumab Fab heavy chain, Cytotoxic T-lymphocyte protein 4 (3 entities in total) |
Functional Keywords | antibody, complex, fab, immune system |
Biological source | Homo sapiens More |
Cellular location | Cell membrane ; Single-pass type I membrane protein : P16410 |
Total number of polymer chains | 6 |
Total formula weight | 120693.16 |
Authors | Ramagopal, U.A.,Liu, W.,Garrett-Thomson, S.C.,Yan, Q.,Srinivasan, M.,Wong, S.C.,Bell, A.,Mankikar, S.,Rangan, V.S.,Deshpande, S.,Bonanno, J.B.,Korman, A.J.,Almo, S.C. (deposition date: 2016-10-27, release date: 2017-05-10, Last modification date: 2023-10-04) |
Primary citation | Ramagopal, U.A.,Liu, W.,Garrett-Thomson, S.C.,Bonanno, J.B.,Yan, Q.,Srinivasan, M.,Wong, S.C.,Bell, A.,Mankikar, S.,Rangan, V.S.,Deshpande, S.,Korman, A.J.,Almo, S.C. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc. Natl. Acad. Sci. U.S.A., 114:E4223-E4232, 2017 Cited by PubMed: 28484017DOI: 10.1073/pnas.1617941114 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3 Å) |
Structure validation
Download full validation report